KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Long-Term Deferred Tax: 2024-2025

Historic Long-Term Deferred Tax for Recursion Pharmaceuticals (RXRX) over the last 1 years, with Sep 2025 value amounting to $957,000.

  • Recursion Pharmaceuticals' Long-Term Deferred Tax was N/A to $957,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $957,000, marking a year-over-year change of. This contributed to the annual value of $1.9 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Long-Term Deferred Tax of $957,000 as of Q3 2025, which was down 0.00% from $957,000 recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Long-Term Deferred Tax ranged from a high of $2.0 million in Q1 2025 and a low of $957,000 during Q2 2025.
  • Its 2-year average for Long-Term Deferred Tax is $1.5 million, with a median of $1.4 million in 2024.